Use of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers (ACEI/ARB) in diabetic patients with late stage chronic kidney disease (CKD) reduces the risk for mortality and progression to dialysis
Jia-Sin Liu, Master of Science1, Ta-Wei Hsu, MD2, Yu-Kang Chang, Postdoc3, Der-Cherng Tarng, MD4 and Chih-Cheng Hsu, Associate Professor5
(1)NHRI, Miaoli County, Taiwan, (2)National Yang-Ming University Hospital, I-Lan, Taiwan, (3)National Health Research Institutes, Miaoli, Taiwan, (4)National Yang-Ming University, Taipei, Taiwan, (5)National Health Research Institutes, Chu Nan, Taiwan
(1)NHRI, Miaoli County, Taiwan, (2)National Yang-Ming University Hospital, I-Lan, Taiwan, (3)National Health Research Institutes, Miaoli, Taiwan, (4)National Yang-Ming University, Taipei, Taiwan, (5)National Health Research Institutes, Chu Nan, Taiwan